Actively Recruiting
AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases
Led by Fudan University · Updated on 2024-11-12
800
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this observational study is to extract the imaging features of brain lesions and primary lung lesions in NSCLC patients with brain metastases by deep learning, as well as common clinicopathological parameters, which are used to construct a multimode model that can accurately predict the treatment efficacy and survival of the third-generation EGFR-TKI treatment, and to use the model to assist in screening high-risk populations suitable for upfront cranial radiotherapy. Participants receiving third-generation EGFR-TKI treatment will be enrolled in our study and we will collect their regular contrast-enhanced chest CT and contrast-enhanced brain MRI for model construction.
CONDITIONS
Official Title
AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically confirmed non-small cell lung cancer
- Clinical stage IV (AJCC, 8th edition, 2017)
- EGFR sensitive mutations: EGFR L858R, EGFR exon 19 deletion
- Age 18 years or older
- Karnofsky Performance Status (KPS) score 70 or higher
- Brain metastases present at diagnosis
- Complete systemic imaging including brain MRI before third-generation EGFR-TKI treatment
- Received standard third-generation EGFR-TKI therapy (monotherapy or combined with brain radiotherapy)
- Willing to cooperate with follow-up after third-generation EGFR-TKI treatment
- Provided informed consent
You will not qualify if you...
- Multiple primary or metastatic tumors except early skin cancer or treated cervical carcinoma in situ with no recurrence for over 5 years
- Pregnant or lactating women who are not candidates for brain MRI as judged by the investigator
- Negative or unknown EGFR sensitive mutation status
- Uncontrolled epilepsy, central nervous system disease, or history of mental disorders affecting consent or compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Cancer center
Shanghai, Shanghai Municipality, China, 200050
Actively Recruiting
Research Team
Z
zhengfei Zhu
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here